Vir Biotechnology (VIR) Short term Debt (2019 - 2025)

Vir Biotechnology (VIR) posted Short term Debt of $17.5 million for Q1 2025, up 8.97% sequentially from $16.1 million in Q4 2024.

Vir Biotechnology (VIR) Short term Debt (2019 - 2025) Analysis & Trends

Vir Biotechnology has reported Short term Debt for 5 years, with the latest figure at $17.5 million in Q1 2025.

Quarterly Short term Debt changed N/A year-over-year to $17.5 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $17.5 million (changed N/A YoY) and the FY2024 annual result came in at $16.1 million, changed N/A from the prior year.
Short term Debt improved to $17.5 million in Q1 2025 per VIR's latest filing, from $16.1 million in the prior quarter.
Over five years, Short term Debt peaked at $68.5 million in Q3 2021 and troughed at $16.1 million in Q4 2024.
A 3-year average of $30.5 million and a median of $24.4 million in 2021 frame the typical range for Short term Debt.
The widest YoY moves for Short term Debt: up 457.45% in 2021, down 128.04% in 2021.
Over 3 years, Short term Debt stood at $68.5 million in 2021, then slumped by 76.55% to $16.1 million in 2024, then rose by 8.97% to $17.5 million in 2025.
According to Business Quant data, Short term Debt over the past three periods registered $17.5 million, $16.1 million, and $68.5 million for Q1 2025, Q4 2024, and Q3 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Vir Biotechnology	1.56 Bn	1.56 Bn	238.95 Mn

Download Data